Long-Term Outcomes after Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease

By  

Acta Haematologica, Vol. 135, Iss. 3, 2015-11 ,pp. : 133-139

Karger

Access to resources Recommend Favorite

Evaluation of Long-Term Outcomes, Cytogenetic and Molecular Responses with Imatinib Mesylate in Early and Late Chronic-Phase Chronic Myeloid Leukemia: A Report from a Single Institute

By  

Acta Haematologica, Vol. 128, Iss. 4, 2012-08 ,pp. : 223-232

Karger

Access to resources Recommend Favorite

Assessment of treatment and monitoring patterns and subsequent outcomes among patients with chronic myeloid leukemia treated with imatinib in a community setting

By Saleh Mansoor N.   Haislip Sally   Sharpe Joyce   Hess Tamara   Gilmore James   Jackson James   Sail Kavita R.   Ericson Solveig G.   Chen Lei  

Current Medical Research and Opinion, Vol. 30, Iss. 4, 2014-04 ,pp. : 529-536

Informa Healthcare

Access to resources Recommend Favorite

Long-Term Molecular Remission after Nonmyeloablative Stem Cell Transplantation in a Patient with Chronic Myelogenous Leukemia in the Chronic Phase

By  

Acta Haematologica, Vol. 112, Iss. 4, 2004-11 ,pp. : 225-226

Karger

Access to resources Recommend Favorite

Squamous cell carcinoma in a chronic myelogenous leukemia patient treated with imatinib mesylate

By  

THE JOURNAL OF DERMATOLOGY, Vol. 42, Iss. 3, 2015-03 ,pp. : 338-339

John Wiley & Sons Inc

Access to resources Recommend Favorite